Proteomics International Laboratories Limited (PIQ.AX)
AUD 0.45
(0.0%)
AUD 0.45
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 892.14 Thousand AUD | 22.15% |
| 2023 | 730.34 Thousand AUD | -50.96% |
| 2022 | 1.48 Million AUD | 13.62% |
| 2021 | 1.31 Million AUD | -7.89% |
| 2020 | 1.42 Million AUD | -3.07% |
| 2019 | 1.46 Million AUD | 24.79% |
| 2018 | 1.17 Million AUD | 27.14% |
| 2017 | 925.35 Thousand AUD | 13.28% |
| 2016 | 816.84 Thousand AUD | 34.26% |
| 2015 | 608.39 Thousand AUD | -46.07% |
| 2014 | 1.12 Million AUD | -14.63% |
| 2013 | 1.32 Million AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q4 | 2.65 Million AUD | 0.0% |
| 2024 Q2 | 541.71 Thousand AUD | 0.0% |
| 2024 FY | 892.14 Thousand AUD | 22.15% |
| 2023 Q1 | 383.54 Thousand AUD | -55.3% |
| 2023 Q2 | 431.13 Thousand AUD | 12.41% |
| 2023 FY | 730.34 Thousand AUD | -50.96% |
| 2023 Q3 | 1.2 Million AUD | 179.95% |
| 2023 Q4 | 299.2 Thousand AUD | -75.21% |
| 2022 Q2 | 631.24 Thousand AUD | 0.0% |
| 2022 Q4 | 858.08 Thousand AUD | -38.35% |
| 2022 FY | 1.48 Million AUD | 13.62% |
| 2022 Q3 | 1.39 Million AUD | 120.5% |
| 2021 FY | 1.31 Million AUD | -7.89% |
| 2021 Q1 | 355.76 Thousand AUD | -28.56% |
| 2021 Q2 | 577.18 Thousand AUD | 62.24% |
| 2021 Q3 | 1.06 Million AUD | 85.24% |
| 2021 Q4 | 733.63 Thousand AUD | -31.38% |
| 2020 FY | 1.42 Million AUD | -3.07% |
| 2020 Q4 | 498.01 Thousand AUD | 39.98% |
| 2020 Q3 | 355.76 Thousand AUD | -61.54% |
| 2020 Q2 | 925.06 Thousand AUD | 0.0% |
| 2019 Q1 | 432.09 Thousand AUD | -73.81% |
| 2019 Q4 | 609.25 Thousand AUD | 66.0% |
| 2019 Q3 | 367.01 Thousand AUD | -57.53% |
| 2019 Q2 | 864.19 Thousand AUD | 100.0% |
| 2019 FY | 1.46 Million AUD | 24.79% |
| 2018 Q2 | 473.84 Thousand AUD | 100.0% |
| 2018 Q1 | 236.92 Thousand AUD | -81.79% |
| 2018 Q4 | 1.65 Million AUD | 461.01% |
| 2018 Q3 | 294.11 Thousand AUD | -37.93% |
| 2018 FY | 1.17 Million AUD | 27.14% |
| 2017 Q3 | 231.33 Thousand AUD | -57.39% |
| 2017 Q2 | 542.92 Thousand AUD | 100.0% |
| 2017 Q4 | 1.3 Million AUD | 462.4% |
| 2017 FY | 925.35 Thousand AUD | 13.28% |
| 2017 Q1 | 271.46 Thousand AUD | -74.48% |
| 2016 Q2 | 337.42 Thousand AUD | 121.85% |
| 2016 FY | 816.84 Thousand AUD | 34.26% |
| 2016 Q3 | 204.21 Thousand AUD | -39.48% |
| 2016 Q1 | 152.09 Thousand AUD | -76.13% |
| 2016 Q4 | 1.06 Million AUD | 420.79% |
| 2015 FY | 608.39 Thousand AUD | -46.07% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q3 | 152.09 Thousand AUD | -53.79% |
| 2015 Q4 | 637.32 Thousand AUD | 319.02% |
| 2015 Q2 | 329.11 Thousand AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2014 Q3 | - AUD | 0.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 FY | 1.12 Million AUD | -14.63% |
| 2013 FY | 1.32 Million AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AdAlta Limited | 1.73 Million AUD | 48.662% |
| Acrux Limited | 5.09 Million AUD | 82.476% |
| Actinogen Medical Limited | 9.93 Million AUD | 91.017% |
| AnteoTech Limited | 460.39 Thousand AUD | -93.777% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 65.66% |
| Arovella Therapeutics Limited | 17 Thousand AUD | -5147.9% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Alterity Therapeutics Limited | 4.01 Million AUD | 77.803% |
| Amplia Therapeutics Limited | 4.45 Million AUD | 79.964% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | -88.394% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | -4769.776% |
| Biome Australia Limited | 13 Million AUD | 93.142% |
| Biotron Limited | - AUD | -Infinity% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -48.241% |
| BTC Health Limited | 16.36 Thousand AUD | -5353.197% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 88.037% |
| CSL Limited | 22.41 Billion AUD | 99.996% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 92.247% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 98.988% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 61.473% |
| Dimerix Limited | 583.47 Thousand AUD | -52.901% |
| EZZ Life Science Holdings Limited | 66.44 Million AUD | 98.657% |
| Hexima Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | 28.718% |
| Immuron Limited | 4.9 Million AUD | 81.804% |
| Immutep Limited | 3.5 Million AUD | 74.552% |
| Imugene Limited | - AUD | -Infinity% |
| Invex Therapeutics Ltd | 1.21 Million AUD | 26.406% |
| Memphasys Limited | 60 Thousand AUD | -1386.905% |
| Nanollose Limited | 12.5 Thousand AUD | -7036.573% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 99.615% |
| Noxopharm Limited | 2.4 Million AUD | 62.832% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Nyrada Inc. | - AUD | -Infinity% |
| Orthocell Limited | 5.31 Million AUD | 83.216% |
| PharmAust Limited | - AUD | -Infinity% |
| Patrys Limited | 1.39 Million AUD | 36.009% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | -1255.84% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 75.968% |
| PYC Therapeutics Limited | 22.05 Million AUD | 95.956% |
| Race Oncology Limited | 4 Million AUD | 77.716% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -198.148% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Starpharma Holdings Limited | 8.28 Million AUD | 89.237% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 99.82% |
| Tissue Repair Ltd | 152.24 Thousand AUD | -486.011% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | -839.573% |